Arca
Skip to content
Tools
Tools

Synovial sarcoma

Drug research and approvals for synovial sarcoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 26 studies of synovial sarcoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 3 drug trials for it since 2013, and FDA has 2 approved and 0 open orphan designations naming it.

  • Recruiting worldwide: 26
  • Trials authorized in Canada: 3
  • FDA orphan approvals: 2
  • EU medicines: 0

Recruiting now

Newest posted first, of 26 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 1

Phase 3 4

Phase 2 3

Phase 1 or earlier 12 of 15

How its trials ended

90 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 27 whose ending is known, 19% met their primary endpoint, 0% missed it and 81% stopped early.

  • Completed, result not reported3033%
  • Ongoing2730%
  • Stopped: other or unclear910%
  • Stopped: sponsor or business decision89%
  • Status unknown67%
  • Met its primary endpoint56%
  • Stopped: enrollment or feasibility33%
  • Stopped: lack of efficacy22%

Trials authorized in Canada

Newest first; search them all in Canada trials
Jul 30, 2019A phase 2 single arm open-label clinical trial of ADP-A2M4 spear t cells in subjects with advanced synovial sarcoma or myxoid/round cell liposarcoma (spearhead…ADP-A2M4Uswm CT, LLCOngoing
Jul 21, 2016A pilot study of genetically engineered NY-ESO-1 specific (C259) t cells in HLA-A2+ patients with synovial sarcomaNY-ESO-1C259T/ Cyclophosphamide/ FludarabineAdaptimmune TherapeuticsClosed
Jun 30, 2016A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adult subjects with INI1-negative tumors or relapsed/refractory synovial sarcomaTazemetostat (EPZ-6438)IpsenClosed

FDA orphan designations

Approved first, then open designations, newest first
Jun 17, 2026TecelraTreatment of adults and pediatric patients 12 years of age and older with unresectable or metastatic synovial sarcoma who have received…Uswm CT, LLCApproved
Aug 1, 2024TecelraTreatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P,…Uswm CT, LLCApproved

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.